Why the study?
Do low molecular weight heparins improve safety and efficacy compared to unfractionated heparin in patients with advanced renal failure?
Population
Patients with renal failure requiring anticoagulation for thromboembolic disorders
Comparison
Low molecular weight heparins (LMWHs) vs Unfractionated heparin (UFH)
Design
Review
Authors
Loading...
LMWHs require dose adjustment or monitoring in renal failure to limit bleeding; leaves open any superiority over UFH.
Do low molecular weight heparins improve safety and efficacy compared to unfractionated heparin in patients with advanced renal failure?
Due to prolonged elimination half-lives and risk of severe bleeding, LMWHs require careful dose adjustment or monitoring in patients with advanced renal failure, where they have not yet demonstrated superiority over UFH.
Hetzel et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: